Sappasithiprasong Hospital
Ubon Ratchathani, 34000, Thailand
NCT Number: NCT03379402
This is an observational study to evaluate the utility of the latest recommendation to define severity of infection for sepsis patients (sepsis-3), and to identify the aetiology and factors associated with outcome of community-acquired sepsis in Northeast Thailand.
Potential study participants will be adult patients who are presented at the hospital with community-acquired sepsis. Clinical specimens (including blood, urine, sputum, throat swabs and pus or wound swab) will be collected from each participant on admission for culture, PCR and serological tests, and other laboratory tests. Participants' treatment will be closely monitored during the duration of their hospital stay. Blood will be again collected at 72 hours after admission. Participants will be contacted at 28 days after admission to determine clinical outcome by phone interview with standardized script.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Ubon Ratchathani, 34000, Thailand
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Please note that the following conditions are not exclusion criteria, and patients with the following conditions can be enrolled into the study.
On admission: Blood samples 30.01 mL and other specimens (if available) for culture and other diagnostics tests including sputum, throat swab, urine (midstream urine), and pus which is part of routine practice for patients with sepsis at study site.
Day 3: Blood (15 mL) for culture (10 mL) and PCR (5 mL). There will be no blood collection, if patient is discharged before day 3.
Time frame: 2.5 years
Time frame: 2.5 years
Time frame: 2.5 years
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Other laboratory measurement
Time frame: 2.5 years
Other laboratory measurement
Time frame: 2.5 years
Time frame: 2.5 years
Time frame: 2.5 years
Time frame: 2.5 years
Time frame: 2.5 years
Time frame: 2.5 years
University of Oxford
Other
Utility of Sepsis-3 Definition, Causes and Factors Associated With Outcomes in Community-acquired Sepsis in Ubon Ratchathani, Northeast Thailand
Acronym: SEPSISIII
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01396798
Community-Acquired Infections, Digestive System Diseases
Leuven, Vlaams-Brabant, Belgium
View Trial DetailsNCT06103500
Bacterial Infections, Bacterial Infections and Mycoses
Mississauga, Ontario, Canada
View Trial DetailsNCT06541600
Infections, Inflammation
Wuhan, Hubei, China
View Trial DetailsNCT06080282
Infections, Inflammation
Wuhan, Hubei, China
View Trial Details